Last updated on April 2019

Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Castration Resistant Prostate Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male

Inclusion Criteria:

  • Histologically confirmed prostate adenocarcinoma
  • Castrate serum testosterone <50ng/ml or <1.7nmol/l under continued androgen-deprivation therapy or surgical castration
  • Progressive disease at study entry in accordance with Prostate Cancer Working Group 3 criteria (PCWG3):
  • Biochemical progression: Three consecutive rises in PSA at least one week apart resulting in two 50% increases over the nadir, and a PSA >1.0 ng/ml as minimal starting value, or
  • Radiologic progression: either two or more new bone lesions on bone scan or a new soft tissue lesion using RECIST (Response evaluation criteria in solid tumors).
  • Metastatic disease confirmed on computed tomography (CT) or bone scan
  • Planned treatment with ARSi (androgen-receptor signaling receptors)
  • Written informed consent of the patient

Exclusion Criteria:

  • Persons who are in a dependency or employment relationship with the investigator or sponsor
  • Planned additional concurrent anticancer therapy

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.